FIGO staging for uterine sarcomas

Can the revised 2008 staging system predict survival outcome better?

Ga Won Yim, Eun Ji Nam, Sang Wun Kim, YoungTae Kim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: The aim of this study was to compare survival of patients with uterine sarcomas using the 1988 and 2008 International Federation of Gynecologists and Obstetricians (FIGO) staging systems to determine if revised 2008 staging accurately predicts patient survival. Materials and Methods: A total of 83 patients with leiomyosarcoma and endometrial stromal sarcoma treated at Yonsei University Health System between March of 1989 and November of 2009 were reviewed. The prognostic validity of both FIGO staging systems, as well as other factors was analyzed. Results: Leiomyosarcoma and endometrial stromal sarcoma comprised 47.0% and 53.0% of this study population, respectively. Using the new staging system, 43 (67.2%) of 64 eligible patients were reclassified. Among those 64 patients, 45 (70.3%) patients with limited uterine corpus involvement were divided into stage IA (n=14) and IB (n=31). Univariate analysis demonstrated a significant difference between stages I and II and the other stages in both staging systems (p<0.001) with respect to progression-free survival and overall survival (OS). Age, menopausal status, tumor size, and cell type were significantly associated with OS (p=0.011, p=0.031, p=0.044, p=0.009, respectively). In multivariate analysis, revised FIGO stage greater than III was an independent poor prognostic factor with a hazard ratio of 9.06 [95% confidence interval (CI) 2.49-33.0, p=0.001]. Conclusion: The 2008 FIGO staging system is more valid than the previous FIGO staging system for uterine sarcomas with respect to its ability to distinguish early-stage patients from advanced-stage patients.

Original languageEnglish
Pages (from-to)563-569
Number of pages7
JournalYonsei Medical Journal
Volume55
Issue number3
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Sarcoma
Survival
Endometrial Stromal Sarcoma
Leiomyosarcoma
Cell Size
Disease-Free Survival
Multivariate Analysis
Confidence Intervals
Health
Population
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{7472c5068eb44b9da3464cd2ab865c24,
title = "FIGO staging for uterine sarcomas: Can the revised 2008 staging system predict survival outcome better?",
abstract = "Purpose: The aim of this study was to compare survival of patients with uterine sarcomas using the 1988 and 2008 International Federation of Gynecologists and Obstetricians (FIGO) staging systems to determine if revised 2008 staging accurately predicts patient survival. Materials and Methods: A total of 83 patients with leiomyosarcoma and endometrial stromal sarcoma treated at Yonsei University Health System between March of 1989 and November of 2009 were reviewed. The prognostic validity of both FIGO staging systems, as well as other factors was analyzed. Results: Leiomyosarcoma and endometrial stromal sarcoma comprised 47.0{\%} and 53.0{\%} of this study population, respectively. Using the new staging system, 43 (67.2{\%}) of 64 eligible patients were reclassified. Among those 64 patients, 45 (70.3{\%}) patients with limited uterine corpus involvement were divided into stage IA (n=14) and IB (n=31). Univariate analysis demonstrated a significant difference between stages I and II and the other stages in both staging systems (p<0.001) with respect to progression-free survival and overall survival (OS). Age, menopausal status, tumor size, and cell type were significantly associated with OS (p=0.011, p=0.031, p=0.044, p=0.009, respectively). In multivariate analysis, revised FIGO stage greater than III was an independent poor prognostic factor with a hazard ratio of 9.06 [95{\%} confidence interval (CI) 2.49-33.0, p=0.001]. Conclusion: The 2008 FIGO staging system is more valid than the previous FIGO staging system for uterine sarcomas with respect to its ability to distinguish early-stage patients from advanced-stage patients.",
author = "Yim, {Ga Won} and Nam, {Eun Ji} and Kim, {Sang Wun} and YoungTae Kim",
year = "2014",
month = "1",
day = "1",
doi = "10.3349/ymj.2014.55.3.563",
language = "English",
volume = "55",
pages = "563--569",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "3",

}

FIGO staging for uterine sarcomas : Can the revised 2008 staging system predict survival outcome better? / Yim, Ga Won; Nam, Eun Ji; Kim, Sang Wun; Kim, YoungTae.

In: Yonsei Medical Journal, Vol. 55, No. 3, 01.01.2014, p. 563-569.

Research output: Contribution to journalArticle

TY - JOUR

T1 - FIGO staging for uterine sarcomas

T2 - Can the revised 2008 staging system predict survival outcome better?

AU - Yim, Ga Won

AU - Nam, Eun Ji

AU - Kim, Sang Wun

AU - Kim, YoungTae

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose: The aim of this study was to compare survival of patients with uterine sarcomas using the 1988 and 2008 International Federation of Gynecologists and Obstetricians (FIGO) staging systems to determine if revised 2008 staging accurately predicts patient survival. Materials and Methods: A total of 83 patients with leiomyosarcoma and endometrial stromal sarcoma treated at Yonsei University Health System between March of 1989 and November of 2009 were reviewed. The prognostic validity of both FIGO staging systems, as well as other factors was analyzed. Results: Leiomyosarcoma and endometrial stromal sarcoma comprised 47.0% and 53.0% of this study population, respectively. Using the new staging system, 43 (67.2%) of 64 eligible patients were reclassified. Among those 64 patients, 45 (70.3%) patients with limited uterine corpus involvement were divided into stage IA (n=14) and IB (n=31). Univariate analysis demonstrated a significant difference between stages I and II and the other stages in both staging systems (p<0.001) with respect to progression-free survival and overall survival (OS). Age, menopausal status, tumor size, and cell type were significantly associated with OS (p=0.011, p=0.031, p=0.044, p=0.009, respectively). In multivariate analysis, revised FIGO stage greater than III was an independent poor prognostic factor with a hazard ratio of 9.06 [95% confidence interval (CI) 2.49-33.0, p=0.001]. Conclusion: The 2008 FIGO staging system is more valid than the previous FIGO staging system for uterine sarcomas with respect to its ability to distinguish early-stage patients from advanced-stage patients.

AB - Purpose: The aim of this study was to compare survival of patients with uterine sarcomas using the 1988 and 2008 International Federation of Gynecologists and Obstetricians (FIGO) staging systems to determine if revised 2008 staging accurately predicts patient survival. Materials and Methods: A total of 83 patients with leiomyosarcoma and endometrial stromal sarcoma treated at Yonsei University Health System between March of 1989 and November of 2009 were reviewed. The prognostic validity of both FIGO staging systems, as well as other factors was analyzed. Results: Leiomyosarcoma and endometrial stromal sarcoma comprised 47.0% and 53.0% of this study population, respectively. Using the new staging system, 43 (67.2%) of 64 eligible patients were reclassified. Among those 64 patients, 45 (70.3%) patients with limited uterine corpus involvement were divided into stage IA (n=14) and IB (n=31). Univariate analysis demonstrated a significant difference between stages I and II and the other stages in both staging systems (p<0.001) with respect to progression-free survival and overall survival (OS). Age, menopausal status, tumor size, and cell type were significantly associated with OS (p=0.011, p=0.031, p=0.044, p=0.009, respectively). In multivariate analysis, revised FIGO stage greater than III was an independent poor prognostic factor with a hazard ratio of 9.06 [95% confidence interval (CI) 2.49-33.0, p=0.001]. Conclusion: The 2008 FIGO staging system is more valid than the previous FIGO staging system for uterine sarcomas with respect to its ability to distinguish early-stage patients from advanced-stage patients.

UR - http://www.scopus.com/inward/record.url?scp=84898752332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898752332&partnerID=8YFLogxK

U2 - 10.3349/ymj.2014.55.3.563

DO - 10.3349/ymj.2014.55.3.563

M3 - Article

VL - 55

SP - 563

EP - 569

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 3

ER -